Literature DB >> 18850556

Long-term progression at individual mean intraocular pressure levels in primary open-angle and exfoliative glaucoma.

W C Stewart1, A E Kolker, E D Sharpe, D G Day, A G P Konstas, G Hollo, Y S Astakhov, M A Teus, J A Stewart.   

Abstract

PURPOSE: To describe progression and non-progression rates at individual mean intraocular pressure (IOP) levels for patients with primary open-angle and exfoliative glaucoma.
METHODS: A meta-analysis of five previously published retrospective studies describing progression and non-progression rates at individual intraocular pressure levels over 5 or more years of follow-up. All patients had primary open-angle (four studies) or exfoliative glaucoma (one study).
RESULTS: This meta-analysis included 822 patients of whom 655 (80%) had primary openangle glaucoma and 167 (20%) had exfoliative glaucoma. In total, 220 patients progressed (27%), while 602 (73%) remained stable over 5 years. The mean IOP was 20.0 for progressed and 17.1 mmHg for stable patients (p=0.0004). The peak IOP was 29.1 for progressed and 23.6 mmHg for stable patients (p=0.0014). At an IOP level >18 mmHg, 49% of patients remained stable; at 18 mmHg, 78%; between 13 and 17 mmHg, 82%; and <13 mmHg, 96%. Additional factors associated with progression were older age (p=0.0004) and exfoliative glaucoma (p=0.0001). However, multivariant regression analysis identified only mean IOP as a risk factor for progression (p=0.039).
CONCLUSIONS: This study suggests that maintaining an IOP well within the normal range over 5 years in patients with primary open-angle or exfoliative glaucoma helps to prevent glaucomatousprogression.

Entities:  

Mesh:

Year:  2008        PMID: 18850556     DOI: 10.1177/112067210801800517

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  11 in total

1.  What comparative effectiveness research is needed? A framework for using guidelines and systematic reviews to identify evidence gaps and research priorities.

Authors:  Tianjing Li; S Swaroop Vedula; Roberta Scherer; Kay Dickersin
Journal:  Ann Intern Med       Date:  2012-03-06       Impact factor: 25.391

2.  Short-Term Reproducibility of Twenty-Four-Hour Intraocular Pressure Curves in Untreated Patients with Primary Open-Angle Glaucoma and Ocular Hypertension.

Authors:  Shuo Xu; Qin Jiao; Yu Cheng; Jie Sun; Qiong Lu; Yisheng Zhong
Journal:  PLoS One       Date:  2015-10-14       Impact factor: 3.240

3.  Efficacy and tolerability of fixed-combination brinzolamide/timolol in Latin American patients with open-angle glaucoma or ocular hypertension previously on brimonidine/timolol fixed combination.

Authors:  Arturo Alezzandrini; Douglas Hubatsch; Rene Alfaro
Journal:  Adv Ther       Date:  2014-08-20       Impact factor: 3.845

4.  Short-term reproducibility of intraocular pressure and ocular perfusion pressure measurements in Chinese volunteers and glaucoma patients.

Authors:  Yanlin Gao; Bing Wan; Peiyu Li; Yan Zhang; Xin Tang
Journal:  BMC Ophthalmol       Date:  2016-08-18       Impact factor: 2.209

5.  Brinzolamide/brimonidine fixed-dose combination bid as an adjunct to a prostaglandin analog for open-angle glaucoma/ocular hypertension.

Authors:  Fotis Topouzis; Ivan Goldberg; Katharina Bell; Andrew J Tatham; Antonia Ridolfi; Douglas Hubatsch; Marcelo Nicolela; Phillipe Denis; S Fabian Lerner
Journal:  Eur J Ophthalmol       Date:  2019-10-09       Impact factor: 2.597

6.  Topical Medication Adherence and Visual Field Progression in Open-angle Glaucoma: Analysis of a Large US Health Care System.

Authors:  Yu-Hsiang Shu; Jun Wu; Tiffany Luong; Cynthia Mattox; Ervin N Fang; Brian L Lee; Jason P Jones; Joanna Campbell; Vanessa Shih; Changgeng Zhao; Donald S Fong
Journal:  J Glaucoma       Date:  2021-12-01       Impact factor: 2.503

7.  Safety and Efficacy of Adding Fixed-Combination Brinzolamide/Timolol Maleate to Prostaglandin Therapy for Treatment of Ocular Hypertension or Glaucoma.

Authors:  Anton Hommer; Douglas A Hubatsch; Juan Cano-Parra
Journal:  J Ophthalmol       Date:  2015-10-01       Impact factor: 1.909

8.  Ocular hypotensive effect of fixed-combination brinzolamide/brimonidine adjunctive to a prostaglandin analog: a randomized clinical trial.

Authors:  R D Fechtner; J S Myers; D A Hubatsch; D L Budenz; H B DuBiner
Journal:  Eye (Lond)       Date:  2016-07-01       Impact factor: 3.775

9.  Brinzolamide/Brimonidine Fixed Combination: Simplifying Glaucoma Treatment Regimens.

Authors:  Reza Moosavi; Ejaz Ansari
Journal:  Ophthalmol Ther       Date:  2018-10-26

10.  Retinal Nerve Fiber Layer Thickness Progression after Robotic-Assisted Laparoscopic Radical Prostatectomy in Glaucoma Patients.

Authors:  Kazuyuki Hirooka; Kaori Ukegawa; Eri Nitta; Nobufumi Ueda; Yushi Hayashida; Hiromi Hirama; Rikiya Taoka; Yuma Sakura; Mari Yamasaki; Hiroyuki Tsunemori; Mikio Sugimoto; Yoshiaki Kiuchi
Journal:  J Ophthalmol       Date:  2019-12-06       Impact factor: 1.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.